

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT

CSTONE TO PRESENT PRECLINICAL DATA ON CS2009 AT THE 2024 ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

CStone Pharmaceuticals (the “**Company**” or “**CStone**”) is pleased to announce that preclinical data of CS2009, a key asset in CStone Pipeline 2.0 targeting PD-1, CTLA-4, and VEGFa, will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The SITC annual meeting will be held from November 6 -10, 2024, in Houston, USA.

- Presentation Format: Poster
- Abstract Title: CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation
- Abstract Number: 504
- Presentation Date: November 8 to 9, 2024 (EST)

As a key asset in CStone’s Pipeline 2.0, CS2009 is a potentially first-in-class/best-in-class, next-generation I/O backbone that targets three critical immune suppressive pathways in tumor microenvironment: PD-1, CTLA-4, and VEGFa, with the ability to reinvigorate exhausted tumor-infiltrating T cells (TILs) and exhibit comparable VEGFa neutralization versus existing anti-VEGFa antibodies. CS2009 is expected to enhance the potency of PD-(L)1-based therapies, thus it could potentially cover a broader range of indications, including non-small cell lung cancer, ovarian cancer, renal cell carcinoma, cervical cancer, hepatocellular carcinoma and gastric cancer. Moreover, aided by the anti-CTLA4 arm, CS2009 could potentially benefit patients with low or negative PD-L1 expression who are not sensitive to anti-PD-(L)1 therapies.

Preclinical data has demonstrated that CS2009 exhibits superior anti-tumor activity in immune-competent mouse models, compared to potential competitors, such as PD-(L)1/CTLA4 and PD-(L)1/VEGFa bispecific antibodies.

CS2009 is currently in Investigational New Drug (IND)-enabling stage, and we expect to submit IND

application by the end of 2024 or in early 2025, followed by initiation of the first-in-human trial in early 2025.

About CS2009 (PD-1, CTLA-4 and VEGFa trispecific antibody)

CS2009 is a trispecific antibody targeting PD-1, CTLA-4, and VEGFa, with first-in-class/best-in-class potential for major tumor types. CS2009 has a differentiated molecular design that combines three clinically validated targets, preferentially invigorating exhausted TILs and demonstrating VEGFa neutralization comparable to existing anti-VEGFa antibodies. It covers a wide range of cancers, including non-small cell lung cancer, ovarian cancer, renal cell carcinoma, cervical cancer, hepatocellular carcinoma and gastric cancer.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 15 new drug applications (NDAs) covering 9 indications. The Company's pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: THE COMPANY CANNOT GUARANTEE THAT WE MAY BE ABLE TO ULTIMATELY DEVELOP AND MARKET CS2009 SUCCESSFULLY. Shareholders of the Company and potential investors are advised to exercise due care when dealing in the shares of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, October 7, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Wei Li as

Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.